






The role of statins- New Approaches

Dr Kausik Ray BSc, MBChB, MRCP, MD, MPhil Senior Clinical Research Associate University of Cambridge


&

Honorary Consultant Cardiologist Addenbrooke's Hospital


Cholesterol Trialist Collaboration Meta-Analysis of Dyslipidemia Trials



Greater absolute benefit in secondary vs primary prevention with more intensive Tx



Meta-Analysis of Intensive Statin Therapy LDL Cholesterol by Trial




Meta-Analysis of Intensive Statin Therapy All Endpoints Event Rates

			Odds		No./Total (%)	
	Odds Ratio	(95% CI)	Reduction	High Dose	Std Dose	
Coronary Death or Any Cardiovascular Event		OR, 0.84 95% CI, 0.80-0.89 <i>P</i> =.0000000000006	-16%	3972/13798 (28.8)	4445/13750 (32.3)	
Coronary Death or MI		OR, 0.84 95% CI, 0.77-0.91 p=0.00003	-16%	1097/13798 (8.0)	1288/13750 (9.4)	
Cardiovascular Death		OR, 0.88 95% CI, 0.78-1.00 p=.054	-12%	462/13798 (3.3)	520/13750 (3.8)	
Non-Cardiovascular Death		OR, 1.03 > 95% CI, 0.88-1.20 p=0.73	+3%	340/13798 (2.5)	331/13750 (2.4)	
Total Mortality		OR, 0.94 95% CI, 0.85-1.04 P=0.20	-6%	808/13798 (5.9)	857/13750 (6.2)	
Stroke		OR 0.82 95% CI, 0.71-0.96 p=0.012	-18%	316/13798 (2.3)	381/13750 (2.8)	
0.5	1	2.	5			
High-dose statin better		High-dose statin worse		Cannon CP, et al JACC 2006		

In ACS intensive statin therapy and mortality


- Meta-analysis of PROVE IT and A to Z
- Afilalo et at Heart 2007
- About 8 500 patients with av of 2 years of FU
- 25% reduction in all cause mortality
- (0.61-0.93)
- Absolute benefit is 1.2%

PROVE IT-TIMI 22: Relationship Between Month 4 LDL and Long-Term Risk of Death or Major CV Event



^{*}Adjusted for age, gender, DM, prior MI, baseline LDL

TNT: Incidence of First Major Cardiovascular Events Across Quintiles



Interpretation


Lower is better

 In stable CHD titrate statin to achieve a lower LDL-C


<1.8mmol/L North American guidelines</p>

<2.0mmol/L in European guidelines</p>

Can we afford to delay intensive statin Tx in ACS?




Rapid early reduction in Death, MI or ACS With Intensive statin Tx <1 month




Ray et al. J Am Coll Cardiol. 2005.

A To Z Primary End Point CV Death, MI, Readmission ACS, Or Stroke



MIRACL: Primary Efficacy Measure: Time To First Event*



^{*}Death (any cause), nonfatal MI, resuscitated cardiac arrest, worsening angina with new objective evidence, and urgent rehospitalization.

PROVE IT-TIMI 22 And MIRACL: CRP Appears To Be Driving The Early Time To Benefit With Intensive Atorvastatin Therapy

	A-to-Z	MIRACL	PROVE IT
Number of patients randomized	4497	3086	4162
Early* LDL achieved on treatment, mmol/l	1.6	1.85	1.6
Early* LDL cholesterol differential, mmol/l	1.6	1.6	0.85
CRP differential, %	17	34	38
Early event reduction, %	0*	16*	18 †


^{*} Measured 120 days after randomization.

[†] Measured 90 days after randomization. Adapted from Nissen. *JAMA*. 2004;292:1365.


Interpretation

- Only intensive statin therapy produces early benefits after ACS
- The early benefit appears to be poorly related to LDL-C reduction
- Early benefits may reflect a reduction in inflammation by pleiotropic effects


Risk of heart failure and statin therapy




Meta-analysis of intensive vs standard therapy for reduction of heart failure



Risk of heart failure according to BNP and intensity of statin therapy



TNT: High-dose Atorvastatin Reduced Hospitalizations for HF



The Treating to New Targets (TNT) study followed 10,001 patients with stable CAD randomized to treatment with atorvastatin 80 mg or 10 mg for a median of 4.9 years. A history of HF was present in 7.8% of patients. Patients with known ejection fraction <30% and advanced HF were excluded from the study. Hospitalization for HF was a predefined secondary end point.

Khush KK et al. Circulation. 2007;115:576-583.

Conclusion

- In patients with CHD there is incremental benefit in achieving a lower LDL-C target with intensive statin therapy
- Among patients on intensive statin therapy the lowest LDL-C levels are associated with lowest risk
- i.e. Lower is better
- In ACS patients intensive statin therapy initiated early after ACS is associated with early benefits
- Early benefits are incompletely explained by LDL-C changes and may reflect pleiotropic effects
- Intensive Tx reduces hospitalization for heart failure especially in those with prior history of heart failure or higher BNP levels